BackNuvectis Pharma Overview

Nuvectis Pharma Total Revenue

Latest total revenue for NVCT: $0, below the sector sector average of $1.3B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

N/A

As of Jun 2026

Annual Revenue (TTM)

N/A

Trailing 12 months ending Jun 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Nuvectis Pharma (NVCT) FAQ

As of the most recent data (June 2026), NVCT shows a total revenue of $0. In the prior-year period, the figure was $0. That is below the sector sector average of $1.3B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NVCT's total revenue is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Nuvectis Pharma is outperforming or lagging.

The its sector sector average total revenue is about $1.3B. Nuvectis Pharma is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how NVCT stacks up against individual peers as well.

Tracking NVCT's total revenue over time shows whether Nuvectis Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Nuvectis Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $0) with ownership activity and broader fundamentals.